Methotrexate in Rheumatoid Arthritis: Effect on Blood, Liver and Renal Laboratory Parameters

Authors

  • Fuad Shaikh
  • Rabia Arshad
  • Fahad Azam
  • Nasim Karim

Keywords:

Rheumatoid arthritis, Methotrexate, Laboratory parameters, Monitoring, Response, Drug safety

Abstract

Objective: To evaluate the effect of Methotrexate on blood, liver and renal laboratory parameters in patients having rheumatoid
arthritis.
Materials and Methods : A 24-week, single-blind, interventional study was carried out on 155 consecutive patients, aged 29-
70 years, diagnosed with rheumatoid arthritis. They received tablet Methotrexate, 10 mg (2.5 mg, 4 tablets) weekly, orally.
Laboratory tests like hemoglobin level, total white cell and platelet counts, erythrocyte sedimentation rate, serum glutamic
pyruvic transaminase and serum creatinine levels were recorded at the initial visit as well as at 6, 14 and 24 weeks follow-up
visits.
Results: At the end of 24 weeks hemoglobin level increased to 12.43 ± 0.92 grams per deciliter (g/dl) from a baseline of 10.76
± 1.12 g/dl, white cell count fell to 7,142.46 ± 1332.23 per cubic mm (cmm) from 8,572 ± 1445/cmm, the ESR fell to 40.14
±15.78 mm of Hg in 1st hour from 81.03 ±17.98 mm of Hg, the platelet count fell to 2, 33,738.10 ± 59,769/ cmm from 2, 90,278
± 68,813/cmm, the SGPT levels increased to 55.29 ± 21.97 international units per litre (IU/l) from 31.67 ± 7.37 IU/l and the
serum creatinine increased to 1.11 ± 0.14 mg/dl from 0.95 ± 0.16 mg/dl, all values being highly significant statistically (p<0.001).
Conclusion: Methotrexate exerted significant effects on the blood, liver and renal laboratory parameters. These parameters
may be utilized for monitoring the response and safety of methotrexate use in RA.

References

Allaire SH, Prashker MJ, Meenan RF. The costs of rhe-

umatoid arthritis. Pharmaco Economics. 1994; 6:513–22

Del Puente A, Knowler WC, Pettit DJ, Bennett PH. High

incidence and prevalence of rheumatoid arthritis in Pima

Indians. Am J Epidemiol. 1989; 129:1170-8

Akhter E, Bilal S, Kiani A, Haque U. Prevalence of art-

hritis in India and Pakistan: a review. Rheumatol Int.

; 31(7):849-55

Hameed K, Gibson G, Kadir M. The prevalence of rheu-

matoid arthritis in affluent and poor urban communities

of Pakistan. Br J Rheumatol. 1995; 34:252-6

Pisetsky DS. Laboratory testing in rheumatic diseases.

Ch 278 in Cecil’s Medicine, eds. Goldman L, Aesiello

D. Saunders, Elsevier. 2007; 23rd ed: 1967

Álvarez-Lafuente R, Fernández-Gutiérrez B, Miguel S

de, Jover JA, Rollin R, Loza E et al. Annals of the Rheu-

matic Diseases. 2005; 64:1357-9

Ferrell PB, Aitcheson CT, Pearson GR, Tan E.M. Sero-

epidemiological study of relationships between Epstein-

Barr virus and rheumatoid arthritis. J Clin Invest. 1981;

(3): 681-7

Catalano MA, Carson DA, Slovin SF, Richman DD,

Vaughan JH. . Proc. Natl. Acad. Sci. USA, Immunology.

; 76 (11):5825-8

Balandraud N, Roudier J. Epstein–Barr virus and rheu-

matoid arthritis. Autoimmunity Reviews. July 2004; 3

(5):362-7

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fr-

ies JF, Cooper NS et al. Arthritis Rheum. 1988; 31 (3):

-24

Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT.

Measurement and prediction of radiological progression

in early rheumatoid arthritis. J Rheumatol. 1994; 10:1808-

O'Dell J. Therapeutic strategies for rheumatoid arthritis.

N Engl J Med. 2004; 350 (25): 2591-602

Hasler P. Biological therapies directed against cells in

autoimmune disease. Springer Semin Immunopathol.

; 27 (4): 443-56

Ward MM , Fries JF. Trends in anti-rheumatic medication

use among patients with rheumatoid arthritis,1981-1996.

J Rheumatol. 1998; 25:408-16

Eustice C. The facts of Methotrexate. Updated May, 17,

, about.com guide

Kaltsonoudis E, Papagoras C, Drosos AA. Current and

future role of methotrexate in the therapeutic armamenta-

rium for rheumatoid arthritis; Int J Clin Rheumatol.

;7(2):179-89

Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell

P, Wells GA, Suarez-Almazor ME. Methotrexate for

treating rheumatoid arthritis. Cochrane Database Syst

Rev. Jun 10, 2014

Combe B, Landewe R, Lukas C. EULAR recommenda-

tions for the management of early arthritis: report of a

task force of the European Standing Committee for Int-

ernational Clinical Studies Including Therapeutics

(ESCISIT). Ann Rheum Dis. 2007; 66:34-45

Quemeneur L, Gerland LM, Flacher M, French M,

Revillard JP, Genestier L. Differential control of cell

cycle, proliferation and survival of primary T lympho-

cytes by purine and pyrimidine nucleotides. J Immunol.

; 170: 4986-95

Nesher G, Osborn TG, Moore TL. In vitro effects of

Methotrexate on polyamine levels in lymphocytes from

rheumatoid arthritis patients. Clin Exp Rheumatol. 1996;

: 395-9

Phillips DC, Woollard KJ, Griffiths HR. The anti-inflam-

matory actions of Methotrexate are critically dependent

upon the production of reactive oxygen species. Br J

Pharmacol. 2003; 138: 501-11

Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK

et al. Methotrexate suppresses the interleukin-6 induced

generation of reactive oxygen species in the synoviocytes

of rheumatoid arthritis. Immunopharmacology. 2000;

: 35-44

Whittle SL, Hughes RA. Folate supplementation and

Methotrexate treatment in rheumatoid arthritis: a review;

Rheumatology, 2004, 43 (3): 267-71

Hazra SC, Choudhury AM, Khondker L, Khan MSI,

Ahmed N. Hematological and Biochemical Parameter

Changes Related to Methotrexate Therapy; Bangladesh

Medical Journal 2011; 40(3):40-3

Nemazee D, Hogquist KA. Antigen receptor selection

by editing or down regulation of V (D) J recombination.

Curr. Opin. Immunol. 2003; 15: 182-9

Ortiz Z, Shea B, Suarez-Almazor ME, Moher D, Wells

GA, Tugwell P. The efficacy of folic acid and folinic

acid in reducing methotrexate gastrointestinal toxicity

in rheumatoid arthritis. A meta-analysis of randomized

controlled trials. J Rheumatol. 1998; 1:36-43

Emery P, Breedveld FC, Lemmel EM, JP, B et al. A

comparison of the efficacy & safety of Leflunomide and

Methotrexate for the treatment of rheumatoid arthritis.

. 2000; 39(6)655-65

Ishaq M, Muhammad JS, Hameed K, Mirza AI. Leflun-

omide or methotrexate? Comparison of clinical efficacy

and safety in low socio-economic rheumatoid arthritis

patients, Mod Rheumatol 2011; 21(4): 375-80

Londono J, Santos AM, Santos PI, Cubidez MF, Guzman

C, Valle-Oñate R. Therapeutic efficacy and safety of

methotrexate + leflunomide in Colombian patients with

active rheumatoid arthritis refractory to conventional

treatment, Rev. Bras. Reumatol.2012; 52 (6):837-45

Attar SM, Adverse effects of low dose methotrexate in

rheumatoid arthritis patients. A hospital-based study.

; 31(8):909-15

Alves JANR, Fialho SCS, Morato EF, de Castro GRW,

Ribeiro GG, Zimmermann AF et al. Liver toxicity is

rare in rheumatoid arthritis patients using combination

therapy with leflunomide and methotrexate. São Paulo.

Rev. Bras. Reumatol. 2011; 51(2): 141-4

Morgan SL, Baggott JE, Vaughn WH. Supplementation

with folic acid during methotrexate therapy for rheum-

atoid arthritis. A double-blind, placebo-controlled trial.

Ann Intern Med. 1994; 121:833-41

Tousson E, Zaki ZT, Abu-Shaeir W A, Hassan H. Metho-

trexate-induced Hepatic and Renal Toxicity: Role of Lcarnitine

in Treatment. Biomedicine and Biotechnology,

, 2(4), 85-92

Downloads

Published

2015-12-03

How to Cite

Shaikh, F. ., Arshad, R. ., Azam, F. ., & Karim, N. . (2015). Methotrexate in Rheumatoid Arthritis: Effect on Blood, Liver and Renal Laboratory Parameters. Journal of Bahria University Medical and Dental College, 5(4), 187–190. Retrieved from https://jbumdc.bahria.edu.pk/index.php/ojs/article/view/141

Issue

Section

Original Articles

Most read articles by the same author(s)

<< < 1 2 3